Quantitative nested reverse transcriptase PCR vs. real-time PCR for measuring AML1/ETO (MTG8) transcripts

Area of Science:

• Molecular Biology
• Oncology
• Biotechnology

Background:

• Acute myeloid leukemia (AML) with t(8;21) translocation involves the AML1/ETO fusion transcript.
• Accurate detection of minimal residual disease (MRD) is crucial for predicting relapse and guiding treatment.
• Existing real-time PCR methods have limitations in sensitivity for MRD detection.

Purpose of the Study:

• To develop and validate a highly sensitive quantitative nested reverse transcriptase polymerase chain reaction (QN-RT-PCR) method.
• To compare the sensitivity of QN-RT-PCR with existing real-time PCR methods for detecting the AML1/ETO fusion transcript.
• To assess the utility of QN-RT-PCR for predicting hematological relapse and quantifying MRD in AML patients.

Main Methods:

• Development of a QN-RT-PCR assay using a plasmid cDNA standard containing the AML1/ETO fusion transcript.
• Detection limits were determined for both plasmid standards and spiked cancer cells.
• Comparison of QN-RT-PCR with real-time PCR in clinical samples from AML patients in remission.

Main Results:

• The QN-RT-PCR method demonstrated a higher sensitivity, detecting the fusion transcript at 10(-17) m, compared to 10(-16) m for real-time PCR.
• QN-RT-PCR detected the transcript 60 days before relapse in one patient, versus 10 days for real-time PCR.
• Significant quantitative differences in MRD levels were observed between patients achieving remission via chemotherapy and bone marrow transplantation versus chemotherapy alone.

Conclusions:

• The developed QN-RT-PCR method is significantly more sensitive than conventional real-time PCR for detecting the AML1/ETO fusion transcript.
• This enhanced sensitivity allows for earlier prediction of hematological relapse in AML patients.
• QN-RT-PCR provides a valuable tool for precise quantitative assessment of MRD, differentiating treatment outcomes.